Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: Poor results with mycophenolate mofetil

Clinical and Experimental Rheumatology

Volumn 23, Issue 3, 2005, Pages 393-396

  Pisoni, Cecilia N ^a   Obermoser, Gerlinde ^b   Cuadrado, Maria J ^a   Sanchez, Francisco J ^a   Karim, Yousuf ^a   Sepp, Norbert T ^b   Khamashta, Munther A ^a   Hughes, Graham R V ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Mycophenolate mofetil; Skin; SLE

Indexed keywords

AURANOFIN; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; ETRETIN; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THALIDOMIDE;

ADULT; AMENORRHEA; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COLD INJURY; CONTROLLED STUDY; DISCOID LUPUS ERYTHEMATOSUS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NEUROPATHY; PRIORITY JOURNAL; SKIN BIOPSY; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; URTICARIA; VASCULITIS;

ADOLESCENT; ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 20444458699     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. PATEL P, WERTH V: Cutaneous lupus erythematosus: a review. Dermatol Clin 2002; 20: 373-85.
2. GILLIAM JN, SONTHEIMER RD: Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4: 471-5.
3. JESSOP S, WHITELAW D, JORDAAN F: Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001.
4. RUZICKA T, MEURER M, BRAUN-FALCO O: Treatment of cutaneous lupus erythematosus with etretinate. Acta Derm Venereol 1985; 65: 324-9.
5. CALLEN JP: Management of skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 2002; 16: 245-64.
6. DALZIEL K, GOING G, CARTWRIGHT PH, MARKS R, BEVERIDGE GW ROWELL NR: Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). Br J Dermatol 1986; 115: 211-6.
7. FABBRI P, CARDINALI C, GIOMI B, CAPRONI M: Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol 2003; 4: 449-65.
8. CUADRADO, MJ, KARIM Y, SANNA G, SMITH E, KHAMASHTA MA, HUGHES GRV: Thalidomide in resistant skin lupus: efficacy and safety of different therapeutic regimes. Am J Med 2005 (in press).
9. MODER KG: Mycophenolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol 2003; 90: 15-19; quiz 20, 78.
10. BOEHM I, BIEBER T: Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001; 137: 235-6.
11. HANJANI NM, NOUSARI CH: Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 2002; 138: 1616-8.
12. SCHANZ S, ULMER A, RASSNER G, FIERLBECK G: Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002; 147: 174-8.
13. GOYAL S, NOUSARI HC: Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001; 45: 142-4.
14. GELBER AC, NOUSARI HC, WIGLEY FM: Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000; 27: 1542-5.
15. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
16. CHAN TM, LI FK, TANG CS et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-62.
17. PISONI CN, SANCHEZ FJ, KARIM Y et al.: Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol (in press).